NASH News & Notes From The European Liver Meeting

Non-alcoholic steatohepatitis (NASH) was a focal point of EASL’s conference. Madrigal becomes the fifth company into Phase III in NASH, but Viking’s competing THR agonist is progressing also.

International Flags Blowing In Wind_1200x675

Many of the companies developing drug therapies for non-alcoholic steatohepatitis (NASH) also are investigating non-invasive ways to diagnose the disease and its precursor, non-alcoholic fatty liver disease (NAFLD). Blood tests or scans are showing some promise to replace liver biopsy as the diagnostic standard in this setting, but early data are inconclusive on their accuracy.

The US FDA’s draft guidance for NASH R&D, issued last December, recommends that drug sponsors work on such diagnostic tools...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category